Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Niraparib - TESARO

Drug Profile

Niraparib - TESARO

Alternative Names: GSK-3985771; JNJ-64091742; MK-4827; niraparib hydrochloride; Zejula; ZL 2306

Latest Information Update: 14 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Dana-Farber Cancer Institute; European Network of Gynaecological Oncological Trial Groups; European Organisation for Research and Treatment of Cancer; Georgetown University; Hunan Cancer Hospital; Indiana University School of Medicine; Janssen; Katholieke Universiteit Leuven; Merck & Co; Myriad Genetics; NeoGenomics; Resolution Bioscience; Sarcoma Alliance for Research through Collaboration; Takeda; TESARO; Thomas Jefferson University; University Health Network; University of Florida; University of Kansas Medical Center; University of Pennsylvania; University of Turin; University of Utah; ZAI Lab
  • Class Antineoplastics; Benzamides; Indazoles; Piperidines; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase 1 inhibitors; Poly(ADP-ribose) polymerase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase III Breast cancer; Prostate cancer; Small cell lung cancer
  • Phase II Cholangiocarcinoma; Endometrial cancer; Gastric cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Renal cell carcinoma; Urogenital cancer; Uveal melanoma
  • Phase I Solid tumours
  • No development reported Ewing's sarcoma; Haematological malignancies

Most Recent Events

  • 28 Nov 2019 ZAI Lab plans a phase Ib trial for Gastric cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease) in China (PO), in December 2019 , (NCT04178460)
  • 28 Nov 2019 No recent reports of development identified for phase-I development in Ewing's Sarcoma(Combination therapy, In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in United Kingdom (PO, Capsule)
  • 28 Nov 2019 No recent reports of development identified for phase-I development in Ewing's Sarcoma(Combination therapy, In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in USA (PO, Capsule)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top